ARWR: PALISADE Phase 3 Results Published in NEJM
On September 2, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced results from the Phase 3 PALISADE study of plozasiran in patients with...
235 Views
ARWR: Two Obesity Assets to Enter the Clinic in 2025
On August 8, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the third quarter of fiscal year 2024 that ended June...
239 Views
ARWR: Summer Webinar Series to Highlight Development Pipeline
On May 9, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the second quarter of fiscal year 2024 that ended March 31,...
269 Views